Effects of Oral Creatine Supplementation in a Patient with MELAS Phenotype and Associated Nephropathy

Abstract

An 18-year-old male patient with MELAS phenotype and 2 previous episodes of cerebral stroke, recurrent seizures and nephropathy, was treated with creatine monohydrate after the acute onset of psychomental regression and changing states of somnolence and aggressive and agitated behaviour. These symptoms disappeared completely after 4 weeks of treatment with creatine after which the patient regained all his previous mental abilites. Brain (white matter) proton magnetic resonance spectroscopy (chemical shift imaging) performed at 6 and 12 months of treatment showed lactic acid (Lac) accumulation and high creatine (Cr) levels in relation to choline-containing compounds (Cho). Urinary creatinine excretion as an indicator of the muscle and brain creatine pool increased upon short-term (12 days) high-dosage creatine supplementation (20 g per day) while plasma creatinine concentrations as possible indicators both of increasing creatine pool and of renal insufficiency increased during the course (28 months) of low-dosage creatine supplementation (5 g per day). Deterioration of renal function was finally indicated by urea retention and by impairment of renal creatinine clearance. These observations suggest that creatine supplementation may have a neuroprotective effect in patients with MELAS and episodes of acute mental deterioration. Adverse effects of creatine supplementation on renal function must be considered especially in patients with preexisting nephropathy.

Key words

Creatine Monohydrate - Mitochondrial Encephalopathy - Stroke - Renal Insufficiency

References

• 1 Delanghe J, Buyzere de M, Baele G. Creatine inhibits adenosine diphosphate and collagen-induced thrombocyte aggregation. de Deyn PP, Marescau B, Stalon V, Qureshi IA Guanidino compounds in biology & medicine. London; John Libbey & Compan 1992: 207-211
• 2 Goto Y, Horai S, Matsuoka T, Koga Y, Nihei K, Kobayashi M, Nonaka I. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): A correlative study of the clinical features and mitochondrial DNA mutation.  Neurology. 1992;  42 545-550
• 3 Hagenfeldt I, Dobeln U, Solders G, Kaijser L. Creatine treatment in MELAS.  Muscle & Nerve. 1994;  17 1236-1237
• 4 Harris R C, Soderland K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation.  Clin Sci. 1992;  83 367-372
• 5 Hirano M, Pavlakis S G. Mitochondrial myopathy, encephalopathy, lactic acidosis, stroke like episodes (MELAS): current concepts.  J Child Neurol. 1994;  9 4-13
• 6 Pritchard N R, Kalra P A. Renal dysfunction accompanying oral creatine supplements.  Lancet. 1998;  351 1252-1253
• 7 Radda G K, Odoom J, Kemp G, Taylor D J, Thompson C, Styles P. Assessment of mitochondrial function and control in normal and diseased states.  Biochim Biophys Acta. 1995;  1271 15-19
• 8 Stöckler S, Hanefeld F, Frahm J. Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism.  Lancet. 1996;  348 789-790
• 9 Stöckler S, Marescau B, Deyn de P P, Trijbels J MF, Hanefeld F. Guanidino compounds in guanidinoacetate methyltransferase deficiency, a new inborn error of creatine synthesis.  Metabolism. 1997;  46 1189-1193
• 10 Tarnopolsky M A, Roy B D, McDonald J R. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies.  Muscle Nerve. 1997;  20 1502-1509
• 11 Wilichowski E, Pouwels P JW, Frahm J, Hanefeld F. Quantitative proton magnetic resonance spectroscopy of cerebral metabolic disturbances in patients with MELAS.  Neuropediatrics. 1999;  30 256-263